Remdesivir in Very Old Patients (≥80 Years) Hospitalized with COVID-19: Real World Data from the SEMI-COVID-19 Registry.

Autor: Ramos-Rincon JM; Department of Clinical Medicine, Miguel Hernandez University of Elche, Ctra N332 s/n, 03550 Alicante, Spain., López-Carmona MD; Department of Internal Medicine, Instituto de Investigacion Biomedica de Málaga (IBIMA), Regional University Hospital of Málaga, 29010 Málaga, Spain.; Department of Medicine, University of Málaga, 29010 Málaga, Spain., Cobos-Palacios L; Department of Internal Medicine, Instituto de Investigacion Biomedica de Málaga (IBIMA), Regional University Hospital of Málaga, 29010 Málaga, Spain.; Department of Medicine, University of Málaga, 29010 Málaga, Spain., López-Sampalo A; Department of Internal Medicine, Instituto de Investigacion Biomedica de Málaga (IBIMA), Regional University Hospital of Málaga, 29010 Málaga, Spain.; Department of Medicine, University of Málaga, 29010 Málaga, Spain., Rubio-Rivas M; Internal Medicine Department, Bellvitge University Hospital, L'Hospitalet de Llobregat, 08907 Barcelona, Spain., Martín-Escalante MD; Internal Medicine Department, Costa del Sol Hospital, 29603 Marbella, Spain., de-Cossio-Tejido S; Internal Medicine Department, Doce de Octubre University Hospital, 28041 Madrid, Spain., Taboada-Martínez ML; Internal Medicine Department, Cabueñes University Hospital, 33394 Gijón, Spain., Muiño-Miguez A; Internal Medicine Department, Gregorio Marañón General University Hospital, 28007 Madrid, Spain., Areses-Manrique M; Internal Medicine Department, Santa Marina Hospital, 48004 Bilbo, Spain., Martinez-Cilleros C; Internal Medicine Department, HLA Moncloa University Hospital, 28008 Madrid, Spain., Tuñón-de-Almeida C; Internal Medicine Department, Zamora Hospital Complex, 49022 Zamora, Spain., Abella-Vázquez L; Internal Medicine Department, Nuestra Señora Candelaria University Hospital, 38010 Santa Cruz de Tenerife, Spain., Martínez-Gonzalez AL; Internal Medicine Department, Leon University Hospital Complex, 24071 León, Spain., Díez-García LF; Internal Medicine Department, Torrecárdenas University Hospital, 04009 Almería, Spain., Ripper CJ; Internal Medicine Department, Insular University Hospital Complex, 35016 Las Palmas de Gran Canaria, Spain., Asensi V; Internal Medicine Department, Central Asturias, University Hospital, 33011 Oviedo, Spain., Martinez-Pascual A; Internal Medicine Department, Francesc de Borja Hospital, 46702 Gandia, Spain., Guisado-Vasco P; Internal Medicine Department, Quironsalud A Coruña Hospital, 15009 A Coruña, Spain., Lumbreras-Bermejo C; Internal Medicine Department, Doce de Octubre University Hospital, 28041 Madrid, Spain., Gómez-Huelgas R; Department of Internal Medicine, Instituto de Investigacion Biomedica de Málaga (IBIMA), Regional University Hospital of Málaga, 29010 Málaga, Spain.; Department of Medicine, University of Málaga, 29010 Málaga, Spain.; CIBER Fisiopatologia de la Obesidad y la Nutricion, Carlos III Health Institute, 28029 Madrid, Spain., On Behalf Of The Semi-Covid-Network
Jazyk: angličtina
Zdroj: Journal of clinical medicine [J Clin Med] 2022 Jun 29; Vol. 11 (13). Date of Electronic Publication: 2022 Jun 29.
DOI: 10.3390/jcm11133769
Abstrakt: (1) Background: Large cohort studies of patients with COVID-19 treated with remdesivir have reported improved clinical outcomes, but data on older patients are scarce. Objective: This work aims to assess the potential benefit of remdesivir in unvaccinated very old patients hospitalized with COVID-19; (2) Methods: This is a retrospective analysis of patients ≥ 80 years hospitalized in Spain between 15 July and 31 December 2020 (SEMI-COVID-19 Registry). Differences in 30-day all-cause mortality were adjusted using a multivariable regression analysis. (3) Results: Of the 4331 patients admitted, 1312 (30.3%) were ≥80 years. Very old patients treated with remdesivir (n: 140, 10.7%) had a lower mortality rate than those not treated with remdesivir (OR (95% CI): 0.45 (0.29−0.69)). After multivariable adjustment by age, sex, and variables associated with lower mortality (place of COVID-19 acquisition; degree of dependence; comorbidities; dementia; duration of symptoms; admission qSOFA; chest X-ray; D-dimer; and treatment with corticosteroids, tocilizumab, beta-lactams, macrolides, and high-flow nasal canula oxygen), the use of remdesivir remained associated with a lower 30-day all-cause mortality rate (adjusted OR (95% CI): 0.40 (0.22−0.61) (p < 0.001)). (4) Conclusions: Remdesivir may reduce mortality in very old patients hospitalized with COVID-19.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje